Author Archives: Bruno Quinney

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

DDW Highlights: 12 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the FDA advanced an initiative to implement real-time clinical trials. Elsewhere, UCB made… Read More

#Podcasts

Spinal motor neurone
#ALS #MND #University of Sheffield

University of Sheffield wins global prize for ALS project 

The University of Sheffield has been named as one of the winners of the Longitude Prize on ALS for a project using AI to combat motor neurone disease (MND).  The global prize recognised the Sheffield-led ‘Decode ALS’ consortium as one of the world’s most promising multidisciplinary teams… Read More

#News

Brain physiology
#Angelini Pharma #Biopharma #Brain #Mergers and acquisitions

Angelini Pharma acquires Catalyst to enter US market 

Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion.  Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market and consolidate its… Read More

#Business & Investment #News

#Biotech #Investment #T cell engagers

Cytospire raises £61m to advance T cell engager pipeline 

UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced.  The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme, CYT X300, is… Read More

#Business & Investment #News

#3D modelling #Drug development #Oncology #Organoids

Rewriting the Oncology Playbook

Dr Mark Eccleston, Director of Inaphaea, discusses how patient-derived 3D models can bridge the translational divide in oncology.  Drug development is a complex, costly, and time-consuming process with a high failure rate. Effective cancer therapy development in particular, remains challenging with only 3.4% of drugs entering clinical trials between 2000 and 2015 reaching… Read More

#Exclusive Content

#AI #ALS #Cancer Research Horizons #Cancer Research UK #FDA #Malaria #Mergers and acquisitions #Oncology #Real-time clinical trials #Regulatory #Spinogenix #University of Bath #University of Leeds

This week in Drug Discovery (4 – 8 May) 

News round-up for 4 – 8 May by Bruno Quinney, Content Team at DDW.  This week, the FDA has advanced an initiative to implement real-time clinical trials. Elsewhere, UCB has made headlines for through an acquisition and its cancer research venture.  The top stories:    FDA moves… Read More

#News

Medical research
#Evotec #Inflammatory diseases #Preclinical development

Evotec nominates PDC for inflammatory skin disease programme 

Evotec has nominated its small molecule preclinical development candidate (PDC) as it advances a programme for inflammatory skin diseases.  The programme, developed as part of an alliance in medical dermatology with Almirall announced in 2022, will develop novel treatments for immune-mediated inflammatory skin diseases with high unmet… Read More

#News

#Cell analysis #Fujifilm

FUJIFILM and NextCell launch commercial platform

FUJIFILM Biosciences and NextCell Pharma have announced the launch of a commercial research platform.  NextCell-Cord RUO combines FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium and NextCell’s MSC product derived from umbilical cord tissue. The companies say the platform will provide researchers with a more consistent, efficient, and accessible source of cells. … Read More

#News

#CRDMO #Syngene

Syngene announces leadership appointments to drive growth

Syngene International has announced the appointment of Abhijit Zutshi as Chief Commercial Officer (CCO) and Maninder Kapoor Puri as Chief Human Resources Officer (CHRO).  As a member of the Executive Committee, Zutshi is set to lead Syngene’s commercial activities and is tasked with further expanding the CRDMO’s pipeline… Read More

#News

#Breast cancer #Fast Track designation #FDA

FDA fast tracks immune medicine targeting breast cancer 

The US Food and Drug Administration (FDA) has granted Fast Tack Designation for an immune medicine targeting triple-negative breast cancer.  RPTR-1-201 is a novel T cell receptor (TCR) bispecific immune medicine, developed by biotechnology company Repertoire Immune Medicines, that is currently in a Phase I/II trial for the treatment of multiple… Read More

#News #Regulatory

#Breast cancer #Clinical trial #Oncology #Ovarian cancer #Pancreatic cancer #Prostate cancer

Overcoming drug resistance with General Oncology

DDW Editor Reece Armstrong speaks to Jeff Glazier, CEO of General Oncology, about the challenges facing pancreatic cancer drug development and the company's activities in the space. RA: Why has pancreatic cancer remained so difficult to treat? JG: Pancreatic cancer is typically diagnosed at an advanced stage, is biologically aggressive, and rapidly develops resistance to therapy. Tumours are highly heterogeneous, both between… Read More

#Exclusive Content

#Biotech #Investment #Switzerland

Swiss biotech saw record revenues in 2025, report says 

The Swiss biotech industry recorded its highest ever revenues in 2025, a new report shows.  The 2026 Swiss Biotech Report says the industry saw record revenues of CHF 7.5 billion (€8.2 billion) in 2025, up from CHF 7.2 billion (€7.9 billion) in 2024.  Employment in… Read More

#News

Modern medical science laboratory
#Cancer Research Horizons #Cancer Research UK #Oncology #UCB

Cancer research alliance to advance ‘life-changing’ therapies 

A global initiative is set to leverage oncology expertise to advance a pipeline of novel cancer therapies.  Biopharmaceutical company UCB has announced a new multi-project alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons.   Under the new partnership, Cancer Research UK’s Centre… Read More

#Cancer Research #News

Mosquito
#Malaria #University of Bath #University of Leeds

New malaria target could pave way for drug development 

A previously undiscovered target for treating malaria could pave the way for a new generation of drugs, experts say.   Researchers from the Universities of Bath and Leeds, UK have made a significant advance in the fight against malaria by uncovering a promising new potential target for drug discovery. … Read More

#News

Neuroendocrine tumours
#Clinical trial #Tumour biology

Trial launched to evaluate neuroendocrine tumour vaccine 

A Phase II trial evaluating a treatment for metastatic neuroendocrine tumours (NETs) has been launched.  SurVaxM, a peptide vaccine, has been developed by biotechnology company MimiVax and will be evaluated in a study conducted at Rosewell Park, New York.  The trial will evaluate SurVaxM in combination with temozolomide… Read More

#Cancer Research #News

Scan to diagnose head and neck cancer
#Cancer research #Head and neck cancer #HPV #Protein targets #Ubiquitin-proteasome

What impact could protein stabilisation have for cancer patients?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Anthony Johnson and Matthew Fyfe from Outrun Therapeutics. Outrun is a biotech specialising in protein stabilisation, an approach being applied to treat HPV+ head and… Read More

#Cancer Research #Featured Podcasts #Podcasts